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ORIGINAL CLINICAL REPORT
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OBJECTIVES: To comprehensively classify interventions performed by
emergency medicine clinical pharmacists and quantify cost avoidance
generated through their accepted interventions.
DESIGN: A multicenter, prospective, observational study was performed
between August 2018 and January 2019.
SETTING: Community and academic hospitals in the United States.
PARTICIPANTS: Emergency medicine clinical pharmacists.
INTERVENTIONS: Recommendations classified into one of 38 intervention categories associated with cost avoidance.
MEASUREMENTS AND MAIN RESULTS: Eighty-eight emergency
medicine pharmacists at 49 centers performed 13,984 interventions
during 917 shifts that were accepted on 8,602 patients and generated
$7,531,862 of cost avoidance. The quantity of accepted interventions
and cost avoidance generated in six established categories were as follows: adverse drug event prevention (1,631 interventions; $2,225,049
cost avoidance), resource utilization (628; $310,582), individualization
of patient care (6,122; $1,787,170), prophylaxis (24; $22,804), hands-on
care (3,533; $2,836,811), and administrative/supportive tasks (2,046;
$342,881). Mean cost avoidance was $538.61 per intervention, $875.60
per patient, and $8,213.59 per emergency medicine pharmacist shift. The
annualized cost avoidance from an emergency medicine pharmacist was
$1,971,262. The monetary cost avoidance to pharmacist salary ratio was
between $1.4:1 and $10.6:1.
CONCLUSIONS: Pharmacist involvement in the care of patients presenting to the emergency department results in significant avoidance of healthcare costs, particularly in the areas of hands-on care and adverse drug
event prevention. The potential monetary benefit-to-cost ratio for emergency medicine pharmacists is between $1.4:1 and $10.6:1.
KEY WORDS: cost; medical care; medication; pharmacist; safety; value

P

atient visits to emergency departments (EDs) in the United States
totaled almost 137 million in 2015 (1). Over the last few decades, emergency medicine (EM) teams that typically consisted of physicians and
nurses have evolved to incorporate other professions, including pharmacists.
Traditionally, pharmacists began their careers immediately after pharmacy
school or 1 year of postgraduate residency training, whereas current EM pharmacists frequently have completed specialty residency or fellowship training
and are board certified. Subsequently, the role of pharmacists in the care of
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ED patients has shifted from verifying, preparing,
and dispensing medications in a remote location to
performing direct, bedside patient care as a member
of the EM multidisciplinary team (2). EM pharmacists are required to call upon knowledge pertaining
to pharmacology ranging from pediatrics to geriatrics
and critical care to primary care, which has resulted
in improved outcomes in numerous populations
and hospital structures (2–11). Consequently, multiple professional healthcare organizations, including
the American College of Emergency Physicians and
American College of Medical Toxicology, consider
EM pharmacists to be essential healthcare providers
(10–12). Despite these endorsements, a 2016 survey
of characterizing EM pharmacist services found that
over half of EDs employed EM pharmacists 12 hours
per day or less, suggesting that EM pharmacists remain
widely underutilized (13).
Previous studies of interventions performed by
EM pharmacists have focused on adverse drug event
(ADE) prevention and reductions in medication use
and costs (3, 8, 9, 14). While these studies have made
important steps toward establishing the value an EM
pharmacist brings to patient care, they are limited in
size and scope and document interventions in a heterogeneous manner not based on a rigorous framework.
The only contemporary study to use a framework for
cost avoidance (CA) from pharmacist interventions
evaluated a medical ICU pharmacist’s clinical activities over a 12-month period and determined the CA of
those activities exceeded $3 million with a benefit-cost
ratio of 24.5:1 (15). However, these findings may not be
generalizable to the ED as the composition of interventions and practice culture differ greatly. The purposes
of this study were to comprehensively classify interventions performed by EM pharmacists and quantify
CA generated through accepted interventions.

METHODS
Study Design
The PHarmacist Avoidance or Reductions in Medical
costs in patients presenting the EMergency Department
study was a multicenter, prospective, observational
study performed across the United States in community and academic hospitals between August 2018 and
January 2019. Recruitment was conducted via direct
electronic mail with invitations sent to the Society of
2     www.ccejournal.org

Critical Care Medicine’s (SCCM) Clinical Pharmacy and
Pharmacology section listserv. From this listserv, which
includes multiple healthcare professionals in addition to
pharmacists, clinical pharmacists who provided direct
(at the bedside) or decentralized (not directly within the
ED) patient care for ED patients were invited to participate. Pharmacists currently completing residency or
fellowship training were not eligible for study participation. Multiple pharmacists from the same institution
were eligible to participate. No minimum or maximum
duration of study participation by each pharmacist was
required so as to maximize data capture for pharmacist
interventions; however, participants were encouraged
to document interventions for 20 shifts. Only interventions made by a pharmacist for patients residing in an
ED were eligible for study inclusion.
Data Collection
In preparation for this study, a comprehensive, evidence-based framework for categorizing and monetizing
CA interventions by critical care and EM pharmacists
was developed by our group a priori and previously
published (16). This framework contained 38 interventions associated with CA that pharmacists can perform
in the ICU and ED settings. Each intervention category
was grouped into one of six intervention sections: ADE
prevention, resource utilization, individualization of patient care, prophylaxis, hands-on care, and administrative
and supportive tasks (Supplemental Table 1, http://links.
lww.com/CCX/A595). All clinical interventions made
by participating pharmacists, regardless of their acceptance by the healthcare team, were recorded in Research
Electronic Data Capture (Version 6.18.1, 2019; Vanderbilt
University, Nashville, TN) (17). All participants received
training on appropriate documentation of interventions
using the CA framework. Interventions were entered at
the patient level by each individual pharmacist. Each intervention could only be documented in one intervention
category; however, if multiple interventions were conducted in a given patient, pharmacists were encouraged
log each intervention. Pharmacists were encouraged to
enter these data in real time to provide the most accurate accounting of interventions. Although all interventions (accepted and not accepted) were captured, only
interventions accepted and implemented by the medical
team were included in the CA analysis. Any intervention unable to be classified was not recorded or available for study inclusion. Rush University Medical Center,
April 2021 • Volume 3 • Number 4
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the central and coordinating institutional review board
(IRB), reviewed and approved this study (IRB number
18021508-IRB01). This study was endorsed by the SCCM
Discovery Network and was a work product of the SCCM
Clinical Pharmacy and Pharmacology Section.
Study Outcomes and Statistical Analysis
The primary outcomes were the quantity, type, and acceptance of interventions provided by and the potential CA generated from clinical pharmacists practicing
in ED settings. CA values overall and per patient were
calculated by summing the CA for each intervention
based on values from our previously published systematic framework and expressed in 2019 U.S. dollars (16).
This framework, developed through a scoping review
of the literature for interventions that could be performed by ICU and/or ED pharmacists, standardizes
the capture of pharmacist interventions in this setting
and includes CA data for each type of intervention
based on controlled and observational studies, as well
as expert opinion. A sensitivity analysis was conducted
to evaluate CA from those interventions we previously identified with the highest quality of evidence
(evidence from well-designed controlled trials with
or without randomization) according to the Grading
of Recommendations, Assessment, Development,
and Evaluation evidence-to-decision framework (18).
These interventions included the following: 1) medication route: IV to oral conversion (resource utilization
section), 2) medication route: hypertensive crisis management (resource utilization), 3) antimicrobial therapy
initiation and streamlining (individualization of patient care), 4) change venous thromboembolism prophylaxis to most appropriate agent (prophylaxis), and
5) initiation of venous thromboembolism prophylaxis
(prophylaxis) (16). Demographic data were collected
on each pharmacist and institution. Patients were categorized according to Emergency Severity Index (ESI).
Data were characterized using descriptive statistics.
The CA per pharmacist shift value was annualized using
240 shifts, corresponding to five shifts per week for 48
weeks, allowing for personal time off and holidays. This
annualized CA for a pharmacist was compared with the
average pharmacist salary and benefits not including
overhead ($185,470) to calculate a monetary CA to pharmacist salary ratio (19). Analyses were performed in Stata
(Version 16; StataCorp LLC, College Station, TX).
Critical Care Explorations

RESULTS
One-hundred twenty-four pharmacists responded to
our invitation to participate, with 88 pharmacists subsequently participating in the study. During the study
period, these 88 pharmacists at 49 centers across the
United States completed 917 shifts. The mean ED visits
per year at participating hospitals was 75,226 (sd 32,399).
Pharmacists most frequently had been in practice for
1–3 years (40.9%) and were board certified (72.7%). EM
pharmacists spent the majority of their shift providing
direct patient care (median, 6 hr; interquartile range
[IQR], 4–8 hr) incorporating prospective order verification into their shifts for a median of 5.5 hours (IQR,
1–9 hr). Most shift lengths were 8 hours (43.1%) or 10
hours (36.8%). EM pharmacists infrequently rounded
with a multidisciplinary clinical service (17.4%) but
rather spent a majority of time providing bedside services in the ED. The median number of shifts was 17
(IQR, 6–20), with significant variability in the number
of patients each EM pharmacist-provided care for per
shift (median, 55; IQR, 30–100). Patient acuity was
most commonly ESI levels 2 or 3 (Table 1).
Of the 14,345 interventions made by EM pharmacists, 13,984 (97.4%) were accepted and implemented
by the medical team. These 13,984 interventions were
performed on 8,602 patients in six sections: ADE prevention (accepted interventions: 1,631; percentage of
total accepted interventions: 11.7%), resource utilization (628; 4.5%), individualization of patient care (6,122;
43.8%), prophylaxis (24; 0.2%), hands-on care (3,533;
25.3%), and administrative/supportive tasks (2,046;
14.6%). The most frequent interventions were dosage
adjustments in patients not receiving continuous renal
replacement therapy (CRRT; accepted interventions
2,207; percentage of accepted interventions: 15.8%), initiation of nonantimicrobial therapy (1,705; 12.2%), antimicrobial therapy initiation and streamlining (1,375;
9.8%), and bedside monitoring (1,207; 8.6%). The least
frequently accepted interventions were rejection of a
restricted medication (percentage accepted: 84.6%),
antivenin stewardship (87.5%), and medication reconciliation resulting in minor ADE prevention (88.7%).
Interventions from the five intervention categories with
the highest quality of evidence totaled 1,564 (11.2% of
accepted interventions) (Table 2).
The potential CA generated from pharmacist recommendations totaled $7,531,862 in six sections: ADE
www.ccejournal.org
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TABLE 1.

Emergency Medicine Pharmacist
Characteristics
Characteristic

Years in practice, n (%)
≤1
> 1–3
> 3–6
> 6–12
≥ 12
ED visits per year, mean (sd)

EM Pharmacist
(n = 88)

11 (12.5)
36 (40.9)
24 (27.3)
13 (14.8)
4 (4.6)
75,226
(32,399)

Institution type, n (%)
Academic medical center
44 (45.4)
Community teaching
34 (35.1)
Community nonteaching
18 (18.6)
Government
1 (1)
Special populations seen by EM pharmacists, n (%)
Burn
21 (23.9)
Pediatrics
49 (55.7)
Trauma
68 (77.3)
Stroke
77 (87.5)
Shift duration (hr), n (%)
8
3,272 (43.1)
10
2,793 (36.8)
12
1,117 (14.7)
Other
412 (5.4)
Shifts worked, median (IQR)
17 (6–20)
Direct patient care duration
6 (4–8)
per shift (hr), median (IQR)
Prospective order verification duration
5.5 (1–9)
per shift (hr), median (IQR)
Multidisciplinary clinical services
rounded with each shift, n (%)
0
4,948 (82.6)
1
569 (9.5)
2
37 (0.6)
3
367 (6.1)
4 or more
68 (1.1)
55
Patients cared for per shift (n),
(30–100)
median (IQR)
Emergency Severity Index, patients with accepted
interventions, n (%)
1
419 (9.2)
2
1,631 (35.7)
3
1,841 (40.3)
4
507 (11.1)
5
168 (3.7)
ED = emergency department, IQR = interquartile range.
4     www.ccejournal.org

prevention ($2,225,049; percentage of CA: 29.5%),
resource utilization ($310,582; 4.1%), individualization of patient care ($1,787,170; 23.7%), prophylaxis
($22,804; 0.3%), hands-on care ($2,836,811; 37.7%),
and administrative/supportive ($342,881; 4.6%). The
areas of greatest CA were major ADE prevention
($1,232,561; 16.4%), antimicrobial therapy initiation
and streamlining ($846,244; 11.2%), and blood factor
stewardship ($683,590; 9.1%). CA from the five intervention categories with the highest quality of evidence
totaled $959,351 (12.7% of CA from all accepted interventions) (Table 2).
Average potential CA from accepted interventions was $539 per intervention, $876 per patient, and
$8,214 per EM pharmacist shift. The annualized potential CA from an EM pharmacist was $1,971,262.
The potential monetary CA to pharmacist salary ratio
was $10.6:1. When considering the sensitivity analysis
of accepted interventions from the five most validated
intervention categories, average potential CA was
$613 per intervention, $112 per patient each day, and
$1,046.18 per ED pharmacist shift. The annualized
potential CA for an ED pharmacist was $251,084.23.
The potential monetary CA to pharmacist salary ratio
was $1.4:1.

DISCUSSION
This is the first multicenter, prospective study to comprehensively classify interventions performed by EM
pharmacists and quantify potential CA generated
through those interventions. The potential CA generated from 88 pharmacists over the study period totaled
over $7.5 million U.S. dollars. This potential CA
resulted from pharmacists intervening almost 14,000
times over the course of greater than 8,000 patients. In
total, 97.2% of these interventions were accepted. EM
pharmacists generated $8,214 in potential CA per shift
when all interventions were considered and $1,046 in
potential CA per shift when only the intervention categories with the highest quality of evidence were used.
A significant portion of potential CA resulted from
interventions that involved hands-on care and prevented ADE development. The monetary CA to pharmacist salary ratio for EM pharmacists appears to be
between $1.4:1 and $10.6:1.
Previous studies focusing on the monetary benefit-to-cost ratio of an EM pharmacist have primarily
focused on a single disease state and have not used a
April 2021 • Volume 3 • Number 4
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TABLE 2.

Accepted Pharmacist Interventions and Potential Cost Avoidance
Intervention

Section 1: Adverse drug event prevention

Accepted
Interventions,
n

1,631

Percentage
Acceptance

95.0

Potential Cost
Avoidance, $

2,225,049

Major ADE preventionc

368

97.9

1,232,561

Minor ADE preventionc

398

96.6

154,631

Medication reconciliation resulting in major ADE
preventionc

168

98.8

568,224

Medication reconciliation resulting in minor ADE
preventionc

456

88.7

182,565

Recommend laboratory monitoringd

241

98.8

93,633

628

96.2

310,582

Preventing unnecessary labs and/or testsd

47

100

18,260

Prevention of inappropriate screening of heparininduced thrombocytopeniab

0

—

0

169

92.9

10,007

Medication route: hypertensive crisis managementb

4

100

81,340

Medication route: resolving shock managementc

2

100

149

Discontinuation of clinically unwarranted therapyc

317

97.2

21,686

Prevention of unnecessary high-cost medicationd

89

96.7

179,140

6,122

98.1

1,787,170

Dosage adjustment: continuous renal replacement
therapyc

4

100

10,187

Dosage adjustment: no continuous renal replacement therapyc

2,207

98.2

371,681

Antimicrobial therapy initiation and streamlininga

1,375

97.6

846,244

Anticoagulant therapy managementc

249

97.3

174,006

Initiation of nonantimicrobial therapyc

1,705

98.3

287,139

581

98.5

97,846

1

100

67

24

100

22,804

Change venous thromboembolism prophylaxis to
most appropriate agentb

13

100

252

Initiation of venous thromboembolism prophylaxisb

3

100

21,508

Initiation of stress ulcer prophylaxisc

7

100

397

Section 2: Resource utilization

Medication route: IV to oral conversionb

Section 3: Individualization of patient care

Antimicrobial pharmacokinetic evaluationc
Total parenteral nutrition managementc
Section 4: Prophylaxis

(Continued )
Critical Care Explorations
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TABLE 2. (Continued).

Accepted Pharmacist Interventions and Potential Cost Avoidance
Intervention

Initiation of ventilator associated pneumonia prophylaxis with chlorhexidinec

Accepted
Interventions,
n

Percentage
Acceptance

Potential Cost
Avoidance, $

1

100

647

Section 5: Hands-on care

3,533

97.4

2,836,811

Bedside monitoringd

1,207

97.7

468,944

Emergency code blue participationc

313

96.9

481,253

Rapid response team participationc

408

96.2

68,711

Emergency code stroke participationc

343

95.8

233,809

Emergency code sepsis participationc

129

98.5

204,453

Blood factor stewardshipc

71

97.3

683,590

Emergency procedural sedation or rapid sequence
intubation participationc

389

98.7

107,889

Medication teaching or discharge educationc

373

98.9

255,650

Culture follow-up after emergency department discharged

330

97.1

226,179

7

87.5

106,333

2,046

98.6

342,881

1,154

97.8

130,494

Drug information consultation: toxicology specificc

142

98.6

60,270

Patient own medication evaluationd

239

100

92,856

Therapeutic interchangec

221

98.7

12,058

Pharmacist provided drug protocol management
pursuant to collaborative practice agreementc

262

99.6

28,644

Rejection of a restricted medicationc

22

84.6

18,559

Antivenin stewardshipc
Section 6: Administrative and supportive tasks
Drug information consultationc

Total

13,984

97.2

7,531,862

ADE = adverse drug event.
a
Level of evidence IB.
b
Level of evidence IIA.
c
Level of evidence III.
d
Level of evidence IV.
Values presented as cost avoidance in 2019 U.S. dollars (percentage of interventions accepted in section or subsection).

comprehensive framework of interventions to capture
CA (8, 9, 20–23). These studies were limited by their
single center nature, focused on a relatively limited
number of interventions, and were not based on an
6     www.ccejournal.org

evidence-based framework. As such, this current study
adds substantially to the literature to support the role
of the EM pharmacist as a member of the multidisciplinary team.
April 2021 • Volume 3 • Number 4
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The most common types of intervention made
by EM pharmacists were in the individualization of
patient care category, accounting for nearly 44% of
interventions and 24% of CA. The most frequent interventions were dosage adjustments in patients not receiving CRRT, initiation of nonantimicrobial therapy,
and antimicrobial therapy initiation and streamlining. Pharmacists are able to intervene on a wide array
of interventions, including dosing of medications
based on a number of patient-specific factors such as
age, weight, route of administration, and renal function (4). Pharmacists also play an important role in
antimicrobial stewardship, demonstrating improved
guideline adherence and antimicrobial selection,
and decreasing the need for follow-up to change or
prescribe antimicrobials (24, 25). Specifically, EM
pharmacists have demonstrated an improvement
in prescribing practices for community-acquired
pneumonia and intra-abdominal infections (26).
EM pharmacists likely had less frequent exposure to
patients at high risk of medications being under- or
over-dosed than the ICU but more than other inpatient areas because initial doses provided in the ED
are less likely to exceed a toxic threshold and very few
patients are provided CRRT in the ED (27).
EM pharmacists were very involved in the provision of hands-on care to emergently ill patients.
Almost 25% of interventions and approximately 38%
of CA resulted from these activities. Pharmacists
participated in emergency code blue (i.e., cardiac
arrest) response, which has been shown to improve
compliance with advanced cardiac life support
guidelines (23, 28). Additionally, EM pharmacists
were highly active in acute stroke management,
which frequently reduces door-to-needle times and
increases the proportion of patients who are eligible
to receive a thrombolytic if other criteria are met (22,
29). Finally, blood factor stewardship was the thirdlargest category of CA for EM pharmacists, ensuring
appropriate use of blood factor products and dosages
are achieved (30, 31). These activities have demonstrated a reduction in time to hemostasis and subsequent reduction in length of stay (21).
Almost one-third (30%) of interventions performed
by EM pharmacists prevented or mitigated ADE development. Major ADE prevention provided the largest
amount of CA of all interventions. Many of the ADEs
prevented by EM pharmacists were likely because of
Critical Care Explorations

the lack of available data and velocity at which new data
are being generated and available for acting on in the
ED (32, 33). These results build on previous findings
from a landmark study in which a 66% relative risk reduction in ADEs was generated from adding pharmacists to interdisciplinary healthcare teams (34). In our
study, in addition to preventing over 1,600 ADEs during patient care activities, over 600 additional ADEs
were prevented following medication reconciliation.
For ED patients, determining appropriate medication
dosages, time of last dose, presence of medications that
may result in withdrawal symptoms, and duplicative
therapies are the most common interventions that prevent an ADE (35, 36).
EM pharmacists were infrequently reporting
interventions supporting more efficient utilization
of healthcare resources, ensuring prophylaxis was
provided for patients at risk for preventable complications of critical illness, and performing administrative and supportive tasks. These findings are not
surprising given these opportunities occur less frequently in ED patients, who are commonly being
stabilized prior to admission than in already hospitalized patients (27). Many of the interventions
in these sections may not occur until day 2 or 3 of
hospitalization, including eliminating therapies,
changing from IV to oral dosage forms, or resolving
shock (20, 37, 38).
Major strengths of our study include the prospective design and data collection, multicenter nature,
large sample size, and use of an evidence-based and
previously published framework to categorize and
monetize CA associated with interventions ED and
ICU pharmacists could perform. Based on our design, there are important limitations to note that
have the potential to both over- and under-estimate
the CA. First, while 88 EM pharmacists were included, these results may not be generalizable to all
EM or non-EM pharmacists and EDs due to possible
selection bias due to the method of recruitment,
characteristics of pharmacists likely to participate,
and the voluntary nature of documenting interventions during each shift. The impact this may have
had on documentation of interventions is uncertain. Second, documentation of the exact number
and types of interventions were likely incomplete as
prospective, real time data collection was performed
and the ED is a dynamic environment that requires
www.ccejournal.org
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a pharmacist’s attention to move between multiple
patients and activities. Additionally, interventions
not included in the published framework were not
included in this study. However, interventions that
may not have been documented are likely offset by
interventions that might otherwise have been implemented at a later point in time by another member
of the healthcare team. Downstream clinical decisions that reversed a previous pharmacist intervention, appropriateness of initial interventions, and
reasons for interventions not being accepted were
not collected. In contrast, a potential bias for more
frequently documenting accepted interventions
or inflating interventions performed theoretically
exists. Pharmacists could record interventions in a
nonconsecutive manner at their discretion, which
may have bias the study results. Although the study
group lacked nonpharmacist collaborators, attempts
to reduce this bias using the Hawthorne effect were
instituted (39). Participating pharmacists were aware
that all data analysis would be performed without
the use of identifying information and were educated on proper identification and documentation
of interventions prior to study participation. Third,
while a comprehensive, evidence-based framework
was used to classify interventions and quantify CA,
these CA values are imperfect. While some are more
tangible costs such as medication costs when changing from IV to oral, other costs such as ADE prevention, are more difficult to assign specific values
given the unknown probability of the ADE occurring without pharmacists intervention. The interventions in our framework mostly pertain to critically
ill patients in the ICU and may not capture activities of EM pharmacists with patients of lower acuity
(16). The framework is also limited in that several
studies date back several years and practice has
evolved significantly since then. Additionally, data
collection for this study was undertaken before the
evidence-based framework was published; however,
we did conduct a pilot to use this framework before
the multicenter study (15). Because only five intervention categories have CA values that come from
controlled studies, the results from the sensitivity
analysis that used only these intervention categories
was used to anchor the lowest suspected potential
CA from EM pharmacists, resulting in a substantial decrease in benefit-to-cost ratio; this highlights
the need for high-quality studies of EM pharmacists’
8     www.ccejournal.org

contribution to CA. Furthermore, we were unable to
assess the impact of indirect CA and benefits, such
as protocol or order set implementation that drives
practice changes and may have ‘trickle down’ effects
on practice beyond an individual pharmacist-patient
care scenario. Additional factors may have affected
the quantity, types of interventions and acceptance,
including interpersonal and professional relationships, patient volume, and complexity during the
study period. Finally, the impact of the EM pharmacist on patient-specific outcomes remains to be
determined and future research should correlate
pharmacist interventions with patient outcomes like
mortality and length of stay. Although it is difficult to
ascertain the exact monetary benefit that any healthcare professional adds to the multidisciplinary team,
our study suggests that EM pharmacists make a significant number of clinical interventions and that the
potential CA is greater than the salary and benefits of
an individual pharmacist.

CONCLUSIONS
Pharmacist involvement in the care of patients presenting to the ED results in significant avoidance of
healthcare costs, particularly in the areas of hands-on
patient care and ADE prevention. The potential monetary CA to pharmacist salary ratio for EM pharmacists
is between $1.4:1 and $10.6:1.
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